PF-05280014

BIOLOGICAL4 trials

Sponsors

Pfizer

Conditions

Early Breast CancerHealthyMetastatic Breast Cancer

Phase 1

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

CompletedNCT01603264

Start: 2012-05-31End: 2012-12-31Updated: 2012-12-18

A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)

CompletedNCT02015156

Start: 2014-01-31End: 2014-04-30Updated: 2014-04-23

Phase 3

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

CompletedNCT01989676

PfizerMetastatic Breast Cancer

Start: 2014-02-24End: 2020-06-27Updated: 2021-07-06

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

CompletedNCT02187744

PfizerEarly Breast Cancer

Start: 2014-09-23End: 2016-03-09Updated: 2019-01-08

Related Papers

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

BioDrugs2022-01-0112 citations

Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data

Cancer Research2020-02-153 citations

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer

Cancer Chemotherapy and Pharmacology2019-05-0315 citations

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.

2018-12-2044 citations

Development of PF-05280014, a potential biosimilar to trastuzumab.

Journal of Clinical Oncology2015-05-203 citations

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).

2014-12-0155 citations

A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01).

Journal of Clinical Oncology2013-09-105 citations